William Blair Issues Negative Estimate for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - William Blair lowered their Q3 2026 EPS estimates for Prestige Consumer Healthcare in a research note issued on Thursday, August 7th. William Blair analyst J. Andersen now forecasts that the company will post earnings per share of $1.19 for the quarter, down from their previous estimate of $1.25. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. William Blair also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.40 EPS and FY2027 earnings at $4.82 EPS.

A number of other research analysts have also recently issued reports on PBH. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH traded up $0.87 during midday trading on Monday, reaching $65.47. 103,899 shares of the company traded hands, compared to its average volume of 383,149. The firm has a market cap of $3.22 billion, a PE ratio of 15.37, a PEG ratio of 2.10 and a beta of 0.43. The stock's 50-day simple moving average is $77.67 and its 200-day simple moving average is $81.68. Prestige Consumer Healthcare has a 12 month low of $62.95 and a 12 month high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 earnings per share.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $84,932,000. Raymond James Financial Inc. acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $42,593,000. Norges Bank acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at about $41,848,000. Invesco Ltd. grew its stake in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after buying an additional 261,537 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock valued at $15,923,000 after buying an additional 186,524 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.